News: Biotechnology

View:
 

Found press releases

 

BioGaia signs exclusive distribution agreement in China

5/13/2013 5:15 AM EST  -   BioGaia
BioGaia has signed an agreement with Beijing Keyuan Xinhai Pharmaceutical Co Ltd for the exclusive rights to sell BioGaia’s ProTectis baby drops and ProTectis and Gastrus tablets through the retail pharmacy channel in China from 2013. The products will be sold under BioGaia’s own brand.
Beijing Keyuan Xinhai Pharmaceutical Co Ltd was founded in 1995. It is a large pharmaceutical company...

BioGaia signs exclusive distribution agreement in South Korea

5/7/2013 8:00 AM EST  -   BioGaia
BioGaia has signed an agreement with Dong Sung Pharmaceutical Company Ltd, for the exclusive rights to sell BioGaia’s ProTectis baby drops and ProTectis and Gastrus tablets through the retail pharmacy channel in South Korea from 2013. The products will be sold under BioGaia’s own brand.
Dong Sung is a leading South Korean pharmaceutical manufacturer founded in 1957. The company was made public in 1990 and has a...

Market Making agreement with Norne Securities

5/6/2013 9:02 AM EST  -   NattoPharma ASA
NattoPharma ASA has entered into a Market Making agreement with Norne Securities AS. The purpose of the agreement is to increase the liquidity of the shares of the Company. The Market Making agreement is in accordance with the standard requirements of the Oslo Stock Exchange and will take effect on 8 May 2013.

Report from Annual General Meeting of Vitrolife AB (publ)

4/30/2013 2:30 AM EST  -   Vitrolife AB (publ)
At Vitrolife’s Annual General Meeting yesterday, April 29, the following, amongst other things, was decided:

· The Board’s proposed dividend of SEK 0.60 per share for the financial year 2012 was approved. Friday May 3, 2013 was adopted as the record day.

· Re-election of Board members Fredrik Mattsson, Tord Lendau, Maris Hartmanis, Barbro Fridén and Carsten Browall and new election of Pia Marions, in accordance...

Artimplant postpones Annual General Meeting until June 27, 2013 and publishes th...

4/29/2013 7:53 AM EST  -   Artimplant
The Board decided to put back the Annual General Meeting 2013 from May 30 to June 27, 2013. The ongoing company evaluation work by the Board regarding the structure of the company and ways to finance the company continues

The company publishes the Annual report 2012 on the company web page;

http://www.artimplant.com/investors-media/arsredovisningar.html. The report will only be published in Swedish. The Annual...

Annual General Meeting of BioGaia

4/26/2013 10:00 AM EST  -   BioGaia
The Annual General Meeting of BioGaia AB on 26 April 2013 voted to approve the following resolutions:

- a dividend of SEK 10.00 per share

- re-election of Board members Jan Annwall, Stefan Elving, Thomas Flinck, David Dangoor, Inger Holmström, Jörgen Thorball and Paula Zeilon

- re-election of David Dangoor as Board Chairman

- payment of Board member compensation in an amount of SEK 300,000 to the Chairman and...

BioGaia AB Interim report 1 January – 31 March 2013

4/26/2013 2:00 AM EST  -   BioGaia
President´s comment

“The year is off to a positive start with a growth rate of 25% (excluding foreign exchange effects) of our finished consumer products and in light of our focused efforts to enter the truly large markets and create additional business opportunities together with Nestlé, I am optimistic about our ability to exploit the potential of our acknowledged effective products in the expanding probiotics...

Genovis rights issue oversubscribed

4/22/2013 5:17 AM EST  -   Genovis AB
The issue was subscribed for SEK 15,129, 289, which it was oversubscribed by 10%.
Of the total issue volume of 3,945,189 shares, 77% were subscribed for with preferential rights. The rights issue raised about SEK 13.8 million before issue expenses for Genovis. Statements of account will be sent on April 23, 2013, to allot shares subscribed for without preferential rights.

MenaQ7® Natural Vitamin K Chosen as Finalist for Nutrition Business Technology A...

4/19/2013 3:20 AM EST  -   NattoPharma ASA
OSLO, NORWAY -- NattoPharma ASA (NATTO: Oslo Axess) has announced that its product, MenaQ7Crystals brand vitamin K2 menaquinone-7 (MK-7), the leading MK-7 ingredient, has been selected as a finalist -- one of three -- for Nutrition Business Technology's "Most Effective Product Development Strategy category, as part of its annual awards program presented at Vitafoods, Europe's leading nutritional and food tradeshow.

Interim report January-March 2013: High growth and increased income

4/19/2013 2:30 AM EST  -   Vitrolife AB (publ)
First quarter

Continuing operations:

· Sales growth was 27 percent in local currency. Sales amounted to SEK 105 (86) million, corresponding to an increase of 22 percent in SEK.
· Operating income (EBIT) amounted to SEK 17 (10) million, corresponding to an operating margin of 16 (12) percent.
· Net income amounted to SEK 12 (7) million, which gave earnings per share of SEK 0.61 (0.38).

After the end of the...